Nordic Nanovector
Kjelsåsveien 168 B
Oslo
0884
Tel: 47-22-18-33-01
Fax: 47-22-58-00-07
Website: http://www.nordicnanovector.no/
Email: mail@nordicnanovector.no
343 articles about Nordic Nanovector
-
Nordic Nanovector — Results For Second Quarter And Half Year 2016
8/24/2016
-
Nordic Nanovector Completes Recruitment Of The First Cohorts Of Arm 3 And Arm 4 Of Expanded Phase 1/2 Study Of Betalutin In NHL Patients
8/18/2016
-
Nordic Nanovector: Second Quarter And First Half 2016 Results Presentation And Webcast
8/16/2016
-
Nordic Nanovector: Second Quarter And First Half 2016 Results Presentation And Webcast
8/16/2016
-
Nordic Nanovector And Areva Med To Investigate Potential Of Lead-212 Conjugated Anti-Cd37 Antibody For Treating Leukaemias
6/28/2016
-
Nordic Nanovector: Pre-Dosing NHL Patients With HH1 Anti-CD37 Antibody Before Betalutin® Increases Its Pharmacokinetic Exposure And Reduces Its Haematological Toxicity
6/10/2016
-
BIO2016: Nordic Nanovector To Present At BIO International Convention On 7 June 2016
6/3/2016
-
Nordic Nanovector: Allotment Of Restricted Stock Unites (RSUs) To The Board Of Directors
5/31/2016
-
Nordic Nanovector Capital Markets Day 2016 To Highlight Strong Progress Towards Vision Of Becoming A Significant Player In Haematological Cancers
5/31/2016
-
Nordic Nanovector: New Board Members Elected Bringing Further Expertise In The Development And Commercialization Of Innovative Cancer Therapies
5/23/2016
-
Nordic Nanovector To Host Capital Markets Day In Oslo On 31 May 2016
5/23/2016
-
Nordic Nanovector: Annual General Meeting Held
5/19/2016
-
Nordic Nanovector First Quarter 2016 Results: Strong Progress On All Priorities And Execution On Track
5/19/2016
-
Nordic Nanovector Announces First Patient Enrolled In The Last Cohort (Arm 4) Of Expanded Phase 1/2 Study Of Betalutin In NHL Patients
5/18/2016
-
Nordic Nanovector: Proposal From The Nomination Committee To The Annual General Meeting 19 May 2016
5/13/2016
-
Nordic Nanovector: First Quarter 2016 Results Presentation And Webcast
5/12/2016
-
Nordic Nanovector Announces An Open Investigational New Drug Application For New Clinical Study Of Betalutin In Diffuse Large B-Cell Lymphoma
5/9/2016
-
Nordic Nanovector To Present At BioEquity Europe on 11 May 2016
5/4/2016
-
Nordic Nanovector: Share Capital Increase Registered
4/29/2016
-
Nordic Nanovector: Notice of Annual General Meeting 2016
4/28/2016